Doramectin_HNMR_14949_MedChemExpress
3-甲氧基肾上腺素合成副产物
3-甲氧基肾上腺素合成副产物
甲氧基肾上腺素（Metanephrine）是一种儿茶酚胺类化合物，是肾上腺素和去甲肾上腺素的代谢产物之一。
在甲氧基肾上腺素的合成过程中，可能会产生一些副产物。
这些副产物包括但不限于：
1. 3-甲氧基肾上腺素（3-Methoxytyramine），这是甲氧基肾上腺素的代谢产物之一，也是一种儿茶酚胺类化合物，通常在体内代谢过程中产生。
2. 3,4-二羟基苯乙胺（3,4-Dihydroxyphenethylamine），这是另一种可能的合成副产物，也是一种儿茶酚胺类化合物，可能在甲氧基肾上腺素合成过程中生成。
这些副产物在生物体内可能具有一定的生物活性，对神经递质系统或代谢途径可能产生影响。
然而，关于这些副产物的具体生物学功能和药理学作用，仍需要进一步的研究和探索。
希望这些信息能够帮助你了解甲氧基肾上腺素合成过程中可能产生的副产物。
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
蜂王浆产品中5种大环内酯类抗生素残留量的高效液相色谱-质谱质谱检测方法
346%&*0% ：*K+ -"5L%&.M+N "L+ &.O%OK.&.5 -%&+5E&+N K"4.63 " 5+6PL"& &"5P%6+ L.63 Q+"L.63 *! P% !" "P%-N P% 0K.5K N+4+L"& "-.6% "6M 9 %L 6+EPL"& NE3"LN "L+ Q%E6M’ *K+# "L+ QL%"M NO+5PLE- "6P.Q.) %P.5N "5P.4+ "3".6NP CL"-)O%N.P.4+ Q"5P+L." "6M -#5%O&"N-"N ，"N 0+&& "N N%-+ CL"-)6+3"P.4+ %L) 3"6.N-N "6M -+-Q+LN %J PK+ 5K&"-#M." 3L%EO’ !"5L%&.M+N "L+ " 3L%EO %J "6P.Q"5P+L."& 5%-) O%E6MN PK"P K"4+ Q++6 0.M+&# EN+M .6 -+M.5"& "6M 4+P+L.6"L# OL"5P.5+N’ ? -+PK%M %J K.3K O+L) J%L-"65+ &.2E.M 5KL%-"P%3L"OK# P"6M+- -"NN NO+5PL%-+PL#（ DR;:)!S 9 !S ） 0"N M+4+&%O+M J%L PK+ 5%6J.L-"P.%6 %J J.4+ -"5L%&.M+ "6P.Q.%P.5 L+N.ME+N（ NO.L"-#5.6 ，%&+"6M%-#5.6 ，P#&%N.6 ，L%/) .PKL%-#5.6 ，T%N"-#5.6 ）.6 L%#"& T+&&# N"-O&+N’ *L.5K&%L%"5+P.5 "5.M N%&EP.%6 0"N EN+M P% OL+5.O.) P"P+ PK+ OL%P+.6 .6 PK+ N"-O&+’ *K+ EOO+L &"#+L N%&EP.%6 0"N +/PL"5P+M 0.PK "5+P%6.PL.&+’ *K+6 .P 0"N 5&+"6+M EO 0.PK " : *, 5%&E-6’ *K+ %6+ OL+5ELN%L 9 P0% OL%ME5P .%6 PL"6N.P.%6N J%L +"5K -"5) L%&.M+ "6P.Q.%P.5N 0+L+ -%6.P%L+M’ *K+ L+NE&PN NK%0 PK"P PK+ 0%L<.63 5EL4+N J%L J.4+ -"5L%&.M+ "6P.Q.%P.5N 0+L+ &.6+"L .6 PK+ L"63+ %J ". ""! / ". "$ -3 9 ; Q# DR;:)!S 9 !S .6 N+&+5P.4+ .%6 -%6.P%) L.63 -%M+&’ *K+ &.-.PN %J 2E"6P.P"P.%6 %J PK+ "6P.Q.%P.5N .6 L%#"& T+&&# 0+L+ "&& !" ! 3 9 <3’ *K+ L+5%4+L.+N 0+L+ Q+P0++6 #% ’ " = / )" ’ ! = "P PKL++ NO.<+M &+4+&N（ !" ，*"" "6M !"" ! 3 9 <3 J%L +"5K -"5L%&.M+ "6P.Q.%P.5 ） ，"6M PK+ L+&"P.4+ NP"6M"LM M+4."P.%6N 0+L+ Q+P0++6 $. ( = / *". $ = ’ E$8 F+&26 ：K.3K O+LJ%L-"65+ &.2E.M 5KL%-"P%3L"OK# P"6M+- -"NN NO+5PL%-+PL#（ DR;:)!S 9 !S ） ；-"5L%&.M+ "6P.Q.%P.5 L+N.ME+N ；L%#"& T+&&# + + 大环内酯类抗生 素 （ !?;N ） 的结构特征是以一 个大环 （ 通常 为 *! ’ !" 元 环 ） 内 酯 为 母 体， 在大环 上通过羟基， 以苷键与 * ’ % 个去氧氨基糖或二甲 氨 基糖缩合 成 碱 性 苷［ * ］。 大 环 内 酯 类 抗 生 素 可 以 用 来治疗敏感菌引起 的 呼 吸 道、 消化道和泌尿生殖系 统的感染。另外， 它还是重要的动物生长促进剂， 临
放线菌素D
结晶性 取本品少许，依法检查（通则0981），应符合规定。 有关物质 照高效液相色谱法（通则0512）测定，临用新制，避光操作。 溶剂：乙腈-水（60:40）。 供试品溶液：取本品约20mg，精密称定，置100mL棕色量瓶中，加溶剂溶解并稀释至刻度，摇匀。 对照溶液：精密量取供试品溶液1mL，置100mL棕色量瓶中，用溶剂稀释至刻度，摇匀。 系统适用性溶液：取放线菌素D对照品适量，加溶剂溶解并稀释制成每1mL中约含0.2mg的溶液。 色谱条件：用十八烷基硅烷键合硅胶为填充剂（4.6mm×250mm，5µm或效能相当的色谱柱），以醋酸盐缓冲 液（取醋酸钠2.72g与醋酸2mL，加水溶解并稀释至1000mL）-乙腈（51:49）为流动相A，以上述醋酸盐缓冲液乙腈（20:80）为流动相B，按下表进行线性梯度洗脱，流速为每分钟1.5mL，检测波长为254nm，进样体积100µL。 系统适用性要求：系统适用性溶液色谱图应与标准图谱一致，放线菌素D与杂质Ⅰ间的分离度应符合规定。
有消化道反应、骨髓抑制，少数患者有脱发、皮炎、发热及肝功能损伤等。
骨髓功能低下，有痛风病史，肝功能损害，感染，有尿酸盐性肾结石病史，近期接受过放射治疗或抗癌药治 疗者慎用。用药期间应严格检查血象。定期查肝肾功能。毒副作用出现后可考虑减量或停药。注射时防止药液漏 出血管外。本品可能使尿及血内尿酸升高。
对本品过敏者、孕妇、有水痘病史者、严重骨髓抑制者、严重肝肾功能损害者禁用。
本品可提高放射敏感性，与放射治疗同时应用，可能加重放射治疗降低白细胞作用和局部组织损害作用。本 品也可能削弱维生素K的疗效。
说明：上述内容仅作为介绍，药物使用必须经正规医院在医生指导下进行。
药典信息
来源 性状
鉴别 检查
R28：Very toxic if swallowed. 吞食有极高毒性。 R40：Possible risks of irreversible effects. 可能有不可逆作用的风险。 R61：May cause harm to the unborn child. 可能对未出生婴儿造成危害。
HPLC_法测定阿瑞匹坦中基因毒性杂质3-氯甲基-1,2,4-三唑啉-5-酮
第52卷第9期 辽 宁 化 工 Vol.52，No. 9 2023年9月 Liaoning Chemical Industry September，2023收稿日期： 2022-09-12HPLC 法测定阿瑞匹坦中基因毒性杂质3-氯甲基-1,2,4-三唑啉-5-酮常月赏，兰公剑*，王阔，陶蕾（南京正大天晴制药有限公司，江苏 南京 210046）摘 要：建立了液相色谱法测定阿瑞匹坦基因毒性杂质3-氯甲基-1,2,4-三唑啉-5-酮的分析方法。
采用安捷伦Poroshell 120系列EC -C18柱为色谱柱，0.1%磷酸溶液为流动相A，乙腈为流动相B，进行线性梯度洗脱，流速为1.0 mL ·min -1，柱温为30 ℃；检测波长为210 nm。
结果表明：溶剂空白及主峰不干扰该杂质的测定；该杂质在限度浓度20%~200%的范围内线性关系良好；该杂质的回收率在99.3%~101.0%范围内，RSD 小于5.0%；对照品溶液及供试液在室温放置18 h 内稳定；重复性和中间精密度RSD 均小于5.0%。
本方法专属性及精密度好，准确度高，可以用于本品中基因毒性杂质3-氯甲 基-1,2,4-三唑啉-5-酮的检测。
关 键 词：阿瑞匹坦；基因毒性杂质；3-氯甲基-1,2,4-三唑啉-5-酮；液相色谱法（HPLC） 中图分类号：TQ460.7 文献标识码： A 文章编号： 1004-0935（2023）09-1399-04阿瑞匹坦与其他止吐药物联合用药，适用于预防高度致吐性抗肿瘤化疗的初次和重复治疗过程中出现的急性和迟发性恶心和呕吐[1-6]。
阿瑞匹坦具有全新的药理作用机制，其作为首个神经激肽-1（NK -1）受体拮抗剂为预防和治疗癌症患者化疗引起的恶心呕吐提供了更多的药物治疗选择[7-9]。
3-氯甲基-1,2,4-三唑啉-5-酮是合成阿瑞匹坦的关键物料，属三唑啉酮类衍生物[10]。
3-氯甲基-1,2, 4-三唑啉-5-酮为单卤代烷烃化合物[11-12]，依据ICH M7，该化合物具有基因警示结构。
世卫组织-三类致癌物
81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123
1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987 1987
1-氨基-2-甲基蒽醌 喹诺酮（五氯硝基苯） 二乙酰基氨基甲苯 苏丹红4号 颜料黄AB,苯偶氮-2-萘胺 苏丹红III N-亚硝基二苯胺 肼苯哒嗪 1-萘基硫脲（ANTU） 2,4,6-三甲基苯胺 青霉酸 3,3′-二甲氧基-4,4′-联苯二异 3,3'-Dimethoxybenzidine-4,4'-diisocyanate 氰酸酯 4-Nitrobiphenyl 4-硝基联苯 2,4-Xylidine 2,4-二甲基苯胺 2,5-Diaminotoluene 2,5-二氨基甲苯 2,5-Xylidine 2,5二甲基苯胺 Eugenol 丁子香酚 Disulfiram 双硫仑 1,2-Diamino-4-nitrobenzene 1,2-二氨基-4-硝基苯 5-Nitro-ortho-anisidine 5- 邻氨基苯甲醚 N-Methyl-N,4-dinitrosoaniline N-甲基-N-4-亚硝基苯胺 Chloropropham 氯苯胺灵 Dinitrosopentamethylenetetramine 发泡剂H meta-Cresidine 3-氨基对甲苯甲醚 Phenicarbazide 1-苯基氨基脲 Azobenzene 偶氮苯 para-Anisidine 对甲氧基苯胺 para-Phenylenediamine 对苯二胺 Succinic anhydride 丁二酸酐 meta-Phenylenediamine 间苯二胺 Dicofol 三氯杀螨醇 2-Aminoanthraquinone 2-氨基蒽醌 Anthranilic acid 邻氨基苯甲酸 4-Amino-2-nitrophenol 2-硝基-4-氨基苯酚 Isosafrole 异黄樟素 2-Amino-5-nitrothiazole 2-氨基-5-硝基噻唑 Propham 苯胺灵 Maleic hydrazide 马来酰肼 Sulfafurazole (Sulfisoxazole) 磺胺异恶唑 Butylated hydroxytoluene (BHT) 丁羟甲苯 Blue VRS 酸性蓝1,食品篮3 Oxyphenbutazone 羟基保泰松 Yellow OB 邻甲苯偶氮-2-萘胺 Captan 环己烯亚胺,克菌丹 1-Naphthylamine α-萘胺
反相高效液相色谱法测定胖血藤中大黄素和大黄素甲醚含量
反相高效液相色谱法测定胖血藤中大黄素和大黄素甲醚含量薛朝金;陶凯【摘要】目的建立测定胖血藤中大黄素和大黄素甲醚含量的反相高效液相色谱法.方法采用Diamonsil C18柱(250mm×4.6mm,5 μm),以甲醇-0.1％磷酸溶液(80∶20)为流动相,流速为1.0 mL/min,检测波长为254 nm,柱温为30℃.结果大黄素、大黄素甲醚的进样量分别在0.100 0～1.600 0 μg(r =0.999 9)和0.031 25 ～0.2500 μg(r =0.999 7)范围内与峰面积呈良好线性关系,平均回收率分别为99.07％(RSD=1.04％,n=6)和100.05％(RSD=1.54％,n=6).结论该方法简便、准确、可靠,可用于胖血藤的质量控制.【期刊名称】《中国药业》【年(卷),期】2014(023)001【总页数】2页(P5-6)【关键词】胖血藤;大黄素;大黄素甲醚;高效液相色谱法【作者】薛朝金;陶凯【作者单位】贵州省毕节市食品药品检验所,贵州毕节 551700;贵阳中医学院,贵州贵阳 550002【正文语种】中文【中图分类】R284.1;R282.71胖血藤为蓼科植物毛血藤 Polygonum cynanchodiis Hemsl．的干燥根，别名有荞麦蔓、毛血藤、云扣莲、荞叶细辛，广泛分布于湖北、四川、贵州等省，生长于河岸或山沟草丛中[1]。
该药材已收载于2003年版《贵州省中药材、民族药材质量标准》，具有敛肺止咳、行气健胃、祛风除湿的功效，主要用于肺痨咳嗽、痰中带血、白日咳、胃脘胀闷疼痛、风湿痹痛[2]。
该质量标准只规定了来源、性状、性味归经、功能主治、用法用量及贮藏。
该药材为贵州省少数民族用药，其分布广、药用价值高，目前未发现有对胖血藤含量测定方法研究的报道。
为保证药材质量和疗效，笔者建立了其含量测定方法，现报道如下。
1 仪器与试药高效液相色谱仪（Waters 1525二元高压梯度泵，2487 Dual λ absorbance Detector，柱温箱，Breeze色谱工作站；岛津 LC－20AD二元高压梯度泵，SPD －M20D二级管阵列检测器）；AB265－S型电子天平（瑞士 Mettle Toledo公司）。
阿司咪唑
合成方法
合成方法
化合物(I)和碘甲烷在乙醇中回流8h，环合得到化合物(Ⅱ)。再水解脱去酯基，得到化合物(Ⅲ)。用对甲氧 基苯乙基溴进行N-烷基化，得化合物(Ⅳ)。再用对氟苄基溴烷基化，得阿司咪唑。
1. 1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮的制备
在反应瓶中加入2-羟基苯并咪唑5.0g(37.3mmol)和NaH 1.6g(53mmol)(NaH含量大约为80%,浸入矿物油中) 的DMF 100ml的悬浮液.加毕.在60ºC.(最好有N2保护)搅拌反应1h.再加入4-氟苄基氯(FBC)5.4g(37mmol),加热 ( 6 0 ºC ) 搅 拌 反 应 5 . 5 h . 冷 却 至 室 温 后 加 入 冰 水 7 0 0 m l , 用 二 氯 甲 烷 ( 5 0 0 m l × 2 ) 提 取 . 有 机 层 用 食 盐 水 洗 . 无 水 N a 2 S O 4 干燥.过滤.滤液减压浓缩.剩余物用石油醚析晶.得1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮固体8.0g,为无色 结 晶 m p 1 7 8 ~ 1 7 9 ºC , 收 率 8 8 % .
治疗措施
阿司咪唑中毒的治疗要点为： 1.大量摄入者予洗胃，后灌服活性炭和导泻。 2.对心肌抑制和Q-T间期延长者予5%碳酸氢钠250ml静注可能有效。 3.对症、支持治疗。
专家点评
专家点评
阿司咪阿司咪唑自1983年上市以来，在许多国家得到了广泛应用。国外研究显示阿司咪唑治疗荨麻疹的总有 效率为74%。国内的一项多中心双盲安慰剂对照试验表明阿司咪唑对急性荨麻疹的总有效率为82.9%，对慢性荨麻 疹的总有效率为86.0%，均显著高于安慰剂，主要不良反应为嗜睡、倦怠、口干等，连续用药3个月的患者中，半 数有食欲及体重增加。阿司咪唑的心脏毒性虽然发生率较低，但由于后果严重，已限制了它的应用。阿司咪唑为 强效和长效的H1受体拮抗剂，无中枢镇静和抗毒蕈碱样作用。代谢产物去甲阿司咪唑仍有抗胆胺作用。长期服用 可增进食欲和增加体重，服用过量可引起心脏Q-T间期延长和室性心律失常。适用于各种原因引起过敏性疾病。
气相色谱-负化学离子源质谱法检测胡萝卜中残留的环氟菌胺
e
d le
th
ls
．
，
005 fo
r
，
0
．
0
．
02
．
，
0
e
04 l in
n o
m
g ／k g
i f ty
o
，
l a t iv
d
d d
i a t io
r a n
(RSD )
o m a 9
，
7％
a n
in t e
da y
o
s
Th
te
m
e a
f th
w
th
o m
d
w
g
，
b
o n e
SPE
—
c o
lu
m
c o n n e c
w
d to
c
n e u n m
t r a l a lu
o n
in
a m o
SPE
de
a
．
lu
e
Th
e
a n a s
v e
ly f
is
ie d in
，
o u
t
b y th
o
G C N C I ／M S
p le s
w
it h
e
r e
s e r a n
(LOQ)
d
e
w
a s
0
n
．
g ／k g
i f
m r
．
Th
t io t io
n n
th
c
le
c
t iv
GC测定盐酸普拉克索中三乙胺残留量
乙酰胆碱酯酶抑制剂
上海应用技术学院研究生课程《高等天然产物化学》试卷2014 / 2015 学年第1 学期课程代码：NX0702013论文题目：乙酰胆碱酯酶抑制剂的研究进展姓名：芮银146061414康满满146061409专业：制药工程学院：化工学院乙酰胆碱酯酶抑制剂的研究进展芮银，陈祎桐，康满满摘要：本文阐述了乙酰胆碱酯酶抑制剂(AChEI)的研究进展，介绍了用于药物治疗的乙酰胆碱酯酶抑制剂的各种来源如植物、微生物等，及其抑制乙酰胆碱的活性物质。
在此基础上，总结了几种现代分析技术，对AChEIs进行筛选，大大加快AD药物资源的开发利用进程。
这些方法主要有基于比色法的Ellman's法及相关的改进方法、薄层显色法、荧光显色法、电喷雾质谱法等。
但是，到目前为止，现代分析技术在AD药物资源中的应用还处在起步阶段。
关键词：乙酰胆碱酯酶抑制剂，筛选方法，薄层显色法，荧光显色法The progress of acetylcholinesteraseinhibitorsRui Yin, Chen Yitong, Kang ManmanAbstract：In this artical, the research elaborates progress of acetylcholinesterase inhibitors (AChEI), and introduces a variety of sources for drug treatment acetylcholinesterase inhibitors such as plants, microorganisms, and its active ingredients. On this basis, the review summarizes several modern analytic techniques such as Ellman's method which based on the colorimetric method, TLC chromogenic method, fluorescent color method, Electrospray ionization mass spectrometry and so on. However, at present, the application of modern analytic techniques in AD drug resources is still in infancy.Key word: Acetylcholinesterase inhibitors, Screening Methods, TLC chromogenic method, Fluorescent color method目录摘要.................................................................................................错误!未定义书签。